Commonly asked questions over the Antardhwani helpline

Ankylosing Spondylitis (AS) is considered a relatively uncommon inflammatory arthritis, but it affects millions of people worldwide. Globally, AS affects about 0.1% to 1% of the population, with prevalence varying by region and ethnicity. It is more common in people who carry the HLA-B27 gene. AS typically begins in late adolescence or early adulthood, and although it was once thought to mainly affect men, women are increasingly being diagnosed as awareness and imaging improve.

The exact cause of Ankylosing Spondylitis (AS) is not fully known, but it develops due to a combination of genetic and immune system factors. The strongest known risk factor is the HLA-B27 gene. Many people with AS carry this gene, but having it alone does not mean someone will develop the disease. In people who are genetically predisposed, the immune system becomes overactive, leading to chronic inflammation in the spine and other joints. Environmental triggers, such as infections, may also play a role in starting the inflammatory process.

No. While Ankylosing Spondylitis (AS) mainly affects the spine and sacroiliac joints, it can involve other parts of the body as well. AS may affect peripheral joints such as the hips, shoulders, knees, and ankles. It can also cause inflammation where tendons and ligaments attach to bones (enthesitis). Beyond joints, AS can affect other organs, including the eyes (uveitis), chest wall, heart, and lungs in some people.

Yes. Women can have Ankylosing Spondylitis (AS), although it is often underdiagnosed or diagnosed later compared to men. In women, AS may present with less obvious spinal changes and more neck pain, fatigue, or peripheral joint pain, which can delay diagnosis. Women are also more likely to have non-radiographic axial spondyloarthritis, where symptoms are present but X-ray changes are minimal or absent.

Axial spondyloarthritis (axSpA) and Ankylosing Spondylitis (AS) are closely related but not exactly the same. Axial spondyloarthritis is a broader term for inflammatory conditions that primarily affect the spine and sacroiliac joints. Ankylosing Spondylitis is a subtype of axSpA in which structural changes in the spine are visible on X-rays. Some people have non-radiographic axSpA, which means they experience similar symptoms to AS but do not yet show spinal changes on imaging. In short, while all cases of AS fall under axial spondyloarthritis, not all cases of axSpA are classified as AS. Early diagnosis and treatment are important to manage symptoms and prevent or slow spinal damage.

Ankylosing Spondylitis (AS) has a strong genetic component, but it is not directly inherited in a simple Mendelian pattern. The HLA-B27 gene is the most well-known genetic factor associated with AS. People who carry this gene have a higher risk of developing the disease, although not everyone with HLA-B27 will develop AS. Family history also plays a role, as having a parent or sibling with AS slightly increases your risk. In addition to genetics, immune system factors and environmental triggers contribute to the development of the condition. In summary, AS is influenced by heredity and genetics, but it is not solely a hereditary disease.

HLA-B27 is a specific gene that plays a key role in the immune system. It is strongly associated with Ankylosing Spondylitis (AS), as people who carry this gene have a significantly higher risk of developing the disease. However, having HLA-B27 does not mean a person will definitely develop AS, and some people with AS do not carry the gene. In diagnosis, testing for HLA-B27 can support a suspected AS diagnosis, especially when combined with symptoms, physical examination, and imaging studies. While it is not the sole diagnostic tool, HLA-B27 testing helps doctors identify at-risk individuals early, allowing for timely treatment and better management of inflammation.

No. Being HLA-B27 positive does not mean you definitely have Ankylosing Spondylitis (AS). While HLA-B27 is strongly associated with AS, most people who carry the gene never develop the disease. The test only indicates a higher risk, not a diagnosis. Doctors diagnose AS based on a combination of symptoms, physical examination, imaging tests (such as MRI or X-ray), and blood tests, including HLA-B27. In short, HLA-B27 positivity alone is not enough to confirm AS, but it can help support the diagnosis when other clinical signs are present.

Yes. Ankylosing Spondylitis (AS) can occur even if HLA-B27 is negative. Although HLA-B27 is a strong genetic marker for AS, a significant number of patients do not carry this gene and still develop the condition. Diagnosis in such cases is based on clinical symptoms, inflammatory back pain patterns, imaging tests like MRI or X-rays, and other blood markers. This is why HLA-B27 testing alone cannot rule out AS, and a thorough medical evaluation is essential for accurate diagnosis.

Routine testing of family members of people with Ankylosing Spondylitis (AS) is not usually recommended unless they have symptoms suggestive of the disease. While AS has a genetic component and conditions like HLA-B27 can run in families, most relatives, even those who carry the gene, never develop AS. Testing is generally advised only if a family member experiences persistent inflammatory back pain, joint stiffness, eye inflammation, or other related symptoms. In such cases, early medical evaluation can help with timely diagnosis and management rather than testing based on family history alone.

Children do not directly inherit Ankylosing Spondylitis (AS), but they may inherit a higher genetic risk of developing it. The condition is strongly associated with the HLA-B27 gene, which can be passed from parents to children. However, most children who inherit HLA-B27 never develop AS. Environmental factors, immune responses, and other genes also play a role. Having a parent with AS increases a child’s risk compared to the general population, but it does not mean the child will definitely develop the disease.

Early symptoms of Ankylosing Spondylitis (AS) usually begin gradually and are often mistaken for common back problems. The most common early sign is persistent lower back or buttock pain that lasts for more than three months and is worse at night or early in the morning, with noticeable morning stiffness that improves with movement or exercise. Many people also experience fatigue, mild joint pain (especially in the hips or shoulders), and reduced flexibility in the spine. In some cases, early symptoms may include heel pain, chest tightness, or episodes of eye inflammation (uveitis), which can cause redness and light sensitivity.

Yes, Ankylosing Spondylitis (AS) can cause eye problems, most commonly uveitis (also called iritis). Uveitis occurs in a significant number of people with AS and usually presents as sudden eye redness, pain, blurred vision, and sensitivity to light, often affecting one eye at a time. It happens due to the same underlying inflammatory process that affects the joints and spine. Early diagnosis and prompt treatment by an eye specialist are important, as untreated uveitis can lead to vision complications.

Yes, Ankylosing Spondylitis (AS) can cause fatigue, and in some cases, unintentional weight loss. Fatigue is common and results from ongoing inflammation, chronic pain, poor sleep, and the body’s immune response. Weight loss is less common but may occur during periods of active disease due to reduced appetite, increased inflammation, or decreased physical activity. Managing inflammation with appropriate treatment, maintaining good sleep habits, and following a balanced diet can help reduce fatigue and support overall health.

Yes, Ankylosing Spondylitis (AS) can affect posture over time if inflammation is not well controlled. Chronic inflammation in the spine can lead to stiffness, reduced flexibility, and fusion of vertebrae, which may cause a forward-stooped posture (kyphosis). Postural changes often develop gradually and are more likely in long-standing or untreated disease. Early diagnosis, regular exercise, physiotherapy, and proper medical treatment can help maintain an upright posture and preserve spinal mobility.

You may suspect Ankylosing Spondylitis (AS) if you have chronic lower back or buttock pain lasting more than three months, especially if it worsens at night or early morning and improves with movement or exercise. Other signs include morning stiffness, reduced spinal flexibility, fatigue, and pain in the hips, shoulders, or chest. Some people also experience eye inflammation (uveitis) or a family history of AS. A confirmed diagnosis is made by a rheumatologist using a combination of medical history, physical examination, blood tests, and imaging such as MRI or X-rays, rather than symptoms alone.

MRI plays a key role in the early diagnosis of Ankylosing Spondylitis (AS) because it can detect active inflammation in the sacroiliac joints and spine before permanent damage appears on X-rays. Unlike X-rays, which show changes only in later stages, MRI can identify bone marrow edema and early inflammatory changes, allowing doctors to diagnose AS sooner. Early MRI diagnosis helps start treatment earlier, which can reduce pain, control inflammation, and slow disease progression.

Ankylosing Spondylitis (AS) is often misdiagnosed because its early symptoms closely resemble common mechanical back pain, especially in young adults. The disease usually starts gradually, and X-rays may appear normal in the early stages, leading to delays in detection. Many people are treated for routine back problems before inflammatory causes are considered. In addition, blood tests like HLA-B27 are not definitive, as some patients test negative while others without AS test positive. Limited awareness and delayed referral to a rheumatologist also contribute to late or incorrect diagnosis.

Ankylosing Spondylitis (AS) is not currently curable or reversible, but it is highly manageable with early and appropriate treatment. Modern therapies can effectively control inflammation, relieve pain, and slow or prevent disease progression, helping many people maintain mobility and quality of life. While structural changes in the spine cannot be reversed once they occur, consistent medical care, exercise, and lifestyle management can keep symptoms under control and allow patients to live active, productive lives.

Treatment for Ankylosing Spondylitis (AS) focuses on reducing inflammation, relieving pain, and preserving mobility. Common options include nonsteroidal anti-inflammatory drugs (NSAIDs) as first-line therapy, followed by biologic medications such as TNF inhibitors or IL-17 inhibitors for patients with active disease. Physiotherapy and regular exercise are essential to maintain posture and flexibility, while DMARDs may be used for peripheral joint involvement. In severe cases with significant joint damage, surgical options may be considered. A personalized treatment plan guided by a rheumatologist offers the best long-term outcomes.

Biologic medicines are recommended for Ankylosing Spondylitis (AS) when symptoms remain active and uncontrolled despite adequate treatment with NSAIDs and regular exercise or physiotherapy. They are typically prescribed for patients with moderate to severe disease, ongoing inflammation, or significant impact on daily functioning. Biologics, such as TNF inhibitors or IL-17 inhibitors, help target the underlying inflammatory process and can reduce pain, stiffness, and disease progression. A rheumatologist determines their use after careful evaluation of symptoms, imaging results, and overall response to previous treatments.

Exercise plays a central role in managing Ankylosing Spondylitis (AS) by helping maintain spinal flexibility, posture, and joint mobility. Regular physical activity reduces stiffness, improves pain control, and supports overall strength and breathing capacity. Stretching, posture-focused exercises, and low-impact activities such as walking, swimming, or yoga are especially beneficial. When combined with medical treatment and guided physiotherapy, consistent exercise can slow functional decline and significantly improve quality of life for people living with AS.

Yes, Rheumatoid Arthritis (RA) is an autoimmune disease. In RA, the immune system mistakenly attacks the synovium, the lining of the joints, causing chronic inflammation, pain, swelling, and stiffness. Over time, this autoimmune response can lead to joint damage, deformities, and loss of function. RA can also affect other organs, including the lungs, heart, eyes, and blood vessels. Early diagnosis and treatment are essential to control inflammation, prevent joint damage, and improve long-term quality of life.

Rheumatoid Arthritis (RA) and osteoarthritis (OA) are different types of joint diseases with distinct causes and characteristics. RA is an autoimmune condition, where the immune system attacks the joint lining, leading to inflammation, pain, swelling, and potential joint deformity. It often affects smaller joints like the hands and wrists symmetrically and can involve other organs.

Osteoarthritis, on the other hand, is a degenerative joint disease caused by wear and tear of cartilage over time. It usually affects weight-bearing joints such as the knees, hips, or spine, and is more common with aging. OA causes pain, stiffness, and reduced mobility but typically does not involve systemic inflammation or other organs.

In short, RA is inflammatory and autoimmune, while OA is mechanical and degenerative.

Rheumatoid Arthritis (RA) is caused by a combination of genetic, environmental, and immune system factors. In RA, the immune system mistakenly attacks the synovium, the lining of the joints, causing chronic inflammation. Certain genes, such as those related to HLA-DR, increase susceptibility, while environmental triggers like smoking, infections, or hormonal factors may initiate the autoimmune response. The exact cause is not fully understood, but this interaction between genetics and environment leads to the persistent inflammation, joint damage, and systemic effects seen in RA.

Rheumatoid Arthritis (RA) has a genetic component, but it is not strictly hereditary. Certain genes, especially those related to HLA-DR, can increase a person’s susceptibility to developing RA. Having a close family member with RA slightly raises your risk compared to the general population, but most people with these genes never develop the disease. Environmental factors like smoking, infections, and hormonal influences also play a critical role in triggering RA. In short, RA is influenced by both genetics and environment, but it is not directly inherited in a predictable pattern.

Several factors increase the risk of developing Rheumatoid Arthritis (RA). It is more common in women than men, typically appearing between the ages of 30 and 60, though it can affect younger adults and even children. Genetic predisposition, especially the presence of certain HLA-DR genes, raises susceptibility. Environmental factors such as smoking, obesity, and exposure to certain infections may also trigger RA. Additionally, a family history of RA slightly increases risk. Overall, RA develops from a combination of genetic, hormonal, and environmental factors rather than a single cause.

No, Rheumatoid Arthritis (RA) is not contagious. You cannot catch RA from someone else through touch, blood, saliva, or any form of close contact. RA is an autoimmune disease, meaning it occurs when the body’s immune system mistakenly attacks its own joint tissues. While genetic and environmental factors influence the risk of developing RA, it is entirely non-infectious and cannot be transmitted between people.

Yes, Rheumatoid Arthritis (RA) is a lifelong condition. It is a chronic autoimmune disease that typically persists for years and can fluctuate in severity, with periods of flares and remission. While there is no cure, early diagnosis and appropriate treatment including medications, lifestyle changes, and physical therapy can control symptoms, slow joint damage, and maintain quality of life over the long term. With modern therapies, many people with RA can lead active and productive lives despite the chronic nature of the disease.

The early signs and symptoms of Rheumatoid Arthritis (RA) often develop gradually and may initially be subtle. People commonly experience joint stiffness, particularly in the morning or after periods of inactivity, which can last for 30 to 60 minutes or longer. Early RA usually affects smaller joints like the hands, wrists, and feet, and the symptoms often appear symmetrically on both sides of the body. Individuals may also notice pain, swelling, tenderness, or warmth around the affected joints. In addition to joint-related symptoms, RA can cause fatigue, weakness, and low-grade fever, reflecting systemic inflammation. Recognizing these early signs is crucial, as prompt medical evaluation and treatment can help control inflammation, prevent joint damage, and improve long-term outcomes

Rheumatoid Arthritis (RA) most commonly affects the small joints of the body, particularly those in the hands, wrists, and feet. The disease often occurs symmetrically, meaning the same joints on both sides of the body are affected.Over time, RA can also involve larger joints such as the elbows, shoulders, knees, and hips, and in some cases, it may affect the temporomandibular joint (TMJ) or the spine. In addition to joint pain and swelling, affected joints may become stiff, tender, and lose range of motion, which can impact daily activities and overall mobility.

Yes, morning stiffness is a hallmark symptom of Rheumatoid Arthritis (RA). People with RA often experience stiffness in the affected joints upon waking, which can make movements like getting out of bed, gripping objects, or walking difficult.Unlike the brief stiffness seen in osteoarthritis, RA-related morning stiffness usually lasts 30 minutes to several hours and may improve gradually with gentle movement or exercise. Persistent or prolonged morning stiffness is an important early sign of RA and can indicate active inflammation in the joints, highlighting the need for timely medical evaluation and treatment.

Yes, Rheumatoid Arthritis (RA) can cause fatigue and weakness. This happens because RA is a chronic inflammatory disease, and ongoing inflammation can lead to generalized tiredness, low energy, and muscle weakness.Many people with RA experience persistent fatigue that is not relieved by rest, making daily activities more challenging. Fatigue may worsen during disease flares or periods of high inflammation. Addressing inflammation through medication, lifestyle changes, and regular exercise can help reduce fatigue and improve overall quality of life for people living with RA.

Yes, Rheumatoid Arthritis (RA) can affect organs beyond the joints, making it a systemic autoimmune disease. While RA primarily targets the synovial lining of joints, chronic inflammation can also involve other parts of the body. Commonly affected organs include the lungs (causing interstitial lung disease or inflammation), heart (increasing risk of cardiovascular disease), eyes (dryness, inflammation, or uveitis), and blood vessels. In some cases, RA may lead to anemia, nerve problems, or skin nodules. Early diagnosis and effective treatment are crucial not only to protect joint function but also to prevent or manage systemic complications associated with RA.

A Rheumatoid Arthritis (RA) flare-up is a period when the symptoms of RA suddenly worsen, often after a period of relative calm or remission. During a flare, affected joints may become more painful, swollen, stiff, and tender, and fatigue or overall weakness can increase. Flares can vary in duration and severity, lasting from a few days to several weeks, and may be triggered by factors such as stress, infection, changes in medication, or hormonal fluctuations. Managing flare-ups promptly with medication adjustments, rest, and supportive therapies is important to control inflammation, prevent joint damage, and maintain quality of life.

Rheumatoid Arthritis (RA) is diagnosed through a combination of medical history, physical examination, laboratory tests, and imaging studies. A doctor will evaluate joint pain, swelling, stiffness, and symmetry of symptoms, particularly in the hands, wrists, and feet. Blood tests are commonly used to detect Rheumatoid Factor (RF), anti-CCP antibodies, and markers of inflammation such as ESR and CRP. Imaging tests like X-rays, ultrasound, or MRI help identify joint damage, inflammation, or early structural changes. Early and accurate diagnosis is essential to start treatment promptly, control inflammation, prevent joint damage, and improve long-term outcomes.

Several blood tests are used to help diagnose Rheumatoid Arthritis (RA) and monitor disease activity. The most common tests include:

• Rheumatoid Factor (RF): An antibody often present in people with RA, though it can be positive in other conditions as well.
• Anti-Cyclic Citrullinated Peptide (anti-CCP) antibodies: Highly specific for RA and can help detect the disease early.
• Erythrocyte Sedimentation Rate (ESR): Measures inflammation levels in the body.
• C-Reactive Protein (CRP): Another marker of inflammation that rises during active RA.
• Complete Blood Count (CBC): Helps identify anemia or other blood-related changes associated with RA.

These tests, combined with physical examination and imaging, help doctors confirm the diagnosis and guide treatment decisions.

Rheumatoid Factor (RF) and anti-Cyclic Citrullinated Peptide (anti-CCP) antibodies are key blood markers used in the diagnosis of Rheumatoid Arthritis (RA).

• Rheumatoid Factor (RF): RF is an antibody that the immune system produces, which mistakenly targets the body’s own tissues. Elevated RF levels are common in RA patients, but RF can also appear in other autoimmune diseases or infections, making it less specific.
• Anti-CCP antibodies: These antibodies target specific proteins in the joints and are highly specific for RA, often appearing early in the disease—even before symptoms develop.

Testing for RF and anti-CCP together helps doctors confirm RA, assess prognosis, and detect the disease early, allowing timely treatment to prevent joint damage and improve outcomes.

Yes, Rheumatoid Arthritis (RA) can still be diagnosed even if blood tests are negative, a condition known as seronegative RA. In such cases, patients may not have detectable Rheumatoid Factor (RF) or anti-CCP antibodies, but they still exhibit classic symptoms like joint pain, swelling, stiffness, and morning stiffness, often in a symmetrical pattern. Physical examination, imaging tests (X-ray, ultrasound, MRI), and careful assessment of clinical history are crucial to make the diagnosis. Early recognition and treatment remain important to control inflammation, prevent joint damage, and maintain long-term function, even in seronegative cases.

Early diagnosis of Rheumatoid Arthritis (RA) is crucial because it allows for prompt treatment that can slow disease progression, reduce joint damage, and improve long-term outcomes. RA is a chronic inflammatory autoimmune condition that can cause irreversible joint deformities and functional limitations if left untreated. Identifying RA early also helps control inflammation, manage symptoms like pain and stiffness, and prevent systemic complications that may affect organs such as the heart, lungs, and eyes. Additionally, early diagnosis enables doctors to tailor medications, lifestyle modifications, and physical therapy to maintain mobility, quality of life, and overall health.

If Rheumatoid Arthritis (RA) is left untreated, the chronic inflammation can lead to progressive joint damage, deformities, and loss of function. Over time, affected joints may become painful, swollen, stiff, and unstable, making daily activities difficult. Untreated RA can also cause systemic complications, affecting organs such as the heart, lungs, eyes, and blood vessels, and may increase the risk of anemia, osteoporosis, and cardiovascular disease. Additionally, persistent inflammation can contribute to fatigue, reduced quality of life, and disability. Early diagnosis and timely treatment are essential to control inflammation, prevent joint destruction, and maintain long-term mobility and overall health.

Rheumatoid Arthritis (RA) is treated using a combination of medications, lifestyle modifications, and supportive therapies to control inflammation, relieve symptoms, and prevent joint damage.

• Medications: The mainstay of RA treatment includes DMARDs (Disease-Modifying Anti-Rheumatic Drugs) like methotrexate, which slow disease progression. Biologic drugs and JAK inhibitors may be used in moderate to severe cases. Steroids and pain relievers help manage inflammation and discomfort during flares.
• Lifestyle measures: Regular exercise, physical therapy, and a balanced diet can help maintain joint flexibility, muscle strength, and overall health. Weight management reduces stress on joints, and quitting smoking can improve outcomes.
• Supportive therapies: Occupational therapy, assistive devices, and patient education help maintain independence and daily functioning.

Early and tailored treatment is essential to minimize joint damage, manage symptoms effectively, and improve quality of life for people living with RA.

DMARDs (Disease-Modifying Anti-Rheumatic Drugs) are a class of medications used to slow the progression of Rheumatoid Arthritis (RA) rather than just relieve symptoms. Unlike painkillers or anti-inflammatory drugs, DMARDs target the underlying immune system dysfunction that causes joint inflammation and damage. Common DMARDs include methotrexate, sulfasalazine, and hydroxychloroquine, and they are often considered the first-line treatment for RA. By reducing inflammation and preventing joint erosion and deformity, DMARDs help patients maintain mobility, function, and long-term quality of life. These medications are often combined with lifestyle measures and other therapies for optimal disease control."

Biologic drugs are recommended for Rheumatoid Arthritis (RA) when conventional treatments, such as traditional DMARDs, are not sufficient to control disease activity. Biologics are targeted therapies that block specific molecules or immune pathways responsible for inflammation, such as TNF-alpha, IL-6, or B-cell activity. They are typically prescribed for patients with moderate to severe RA, especially those who continue to experience joint pain, swelling, or progressive damage despite standard DMARD therapy. Biologics can help reduce inflammation, prevent joint destruction, improve physical function, and enhance quality of life. Because these medications can affect the immune system, they require close monitoring for infections and other potential side effects.

Yes, Rheumatoid Arthritis (RA) medications can help stop or slow joint damage when used appropriately and early in the disease course. DMARDs (like methotrexate), biologic drugs, and JAK inhibitors target the underlying autoimmune inflammation that causes joint erosion and deformities. By controlling this inflammation, these medications preserve joint structure, maintain mobility, and reduce long-term disability. Early and consistent treatment, often combined with lifestyle measures such as exercise and weight management, is key to protecting joints and improving long-term outcomes in RA patients.

Yes, Rheumatoid Arthritis (RA) can go into remission, especially with early diagnosis and effective treatment. Remission means that joint inflammation, pain, and swelling are minimal or absent, and disease activity is very low. Remission can be partial or complete and may last for months or even years, though regular monitoring is necessary to detect flares early. Achieving remission typically involves a combination of DMARDs, biologic therapies, lifestyle measures, and regular follow-ups. While remission does not guarantee a permanent cure, it significantly improves quality of life, preserves joint function, and reduces the risk of long-term damage.

Yes, Rheumatoid Arthritis (RA) can go into remission, especially with early diagnosis and effective treatment. Remission means that joint inflammation, pain, and swelling are minimal or absent, and disease activity is very low. Remission can be partial or complete and may last for months or even years, though regular monitoring is necessary to detect flares early. Achieving remission typically involves a combination of DMARDs, biologic therapies, lifestyle measures, and regular follow-ups. While remission does not guarantee a permanent cure, it significantly improves quality of life, preserves joint function, and reduces the risk of long-term damage.